Moderna raises full-year Covid vaccine sales forecast to $21 billion
Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters
Moderna Inc on Thursday raised its full-year forecast for sales of its Covid-19 vaccine to roughly $21 billion from $19 billion.
The company in February forecast sales of $19 billion from its signed contracts, and option for $3 billion in additional purchases.
Moderna on Thursday forecast additional purchases of roughly $500 million.
Keep updated, follow The Business Standard's Google news channel
